hypercholesterolemia
Conditions
Interventions
Pravastatin monotherapy group Pravastatin 20mg/day from Pravastatin 10mg/day
Combined therapy group Pravastatin 10mg/day + Colestimide 3 g/day from Pravastatin 10mg/day
Sponsors
The study group of the treatment for atherosclerotic diseases
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients with >=120mg/dL of LDL-C when tested both 12 to 8 weeks before entry and 4 weeks before entry 2) Male patients with >=85cm of waist both 4 weeks prior to entry and the date of entry Female patients with >=90cm of waist both 4 weeks prior to entry and the date of entry
Exclusion criteria
Exclusion criteria: 1) Patients who are administered statins except Pravastatin. 2) Patients who are administered insulin. 3) Patients who are administered steroid. 4) Patients who started treatment for diabetes or hyperlipidemia within 3 month before entry. 5) Patients with complete biliary obstruction. 6) Patients who have a history of hypersensitivity for Colestimide. 7) Patients with intestinal obstruction. 8) Patients who are underwent hormone replacement therapy. 9) Patients with hyper- or hypothyroidism. 10) Patients who are pregnant or lactating. 11) Patients who are judged to be inadequate to participate in this study by their physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The difference in the visceral fat area after the administration of Colestimide for 24 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Waist circumference Body weight Blood pressure Serum levels of lipid Plasma levels of adipocytokine Glucose metabolism marker | — |
Countries
Japan
Contacts
Public ContactShizuya Yamashita
Osaka University Hospital Department of Cardiovascular Medicine
Outcome results
None listed